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Abstract Mitotic cyclins are key cell-cycle regulators that are 
relatively stable through most of the cell-cycle then rapidly de- 
graded at mitosis. We have detected ubiqnitin conjugates of full- 
length Xenopus cyclin B2 strongly suggesting that ubiqnitination 
rather than a proteolytic cleavage is the initiating event in cyclin 
destruction. The highest levels of ubiqnitin conjugates correlate 
with the phase of rapid proteolysis. This result supports previous 
findings that implicate the ubiquitin system in cyclin proteolysis. 
However, we also observe cyclin-ubiquitin conjugates in both 
cytostatic factor arrested and interphase xtracts where cyclin is 
more stable. The physiologic role of nbiquitinated cyclin under 
these conditions is unclear. 
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I. Introduction 
Cyclins function as subunits of kinases essential for normal 
:ell-cycle regulation [1]. Cyclin B2 is a mitotic cyclin that binds 
~he p34 ~2 kinase to regulate M-phase promoting factor (MPF) 
tctivity [2]. Although relatively stable throughout most of the 
:ell-cycle, mitotic cyclins are abruptly degraded uring mitosis, 
md this proteolytic event is critical for completion of mitosis 
2,3]. We have used Xenopus egg extracts to study the mecha- 
lisms underlying cyclins' rapid destruction. Xenopus eggs are 
laturally arrested in metaphase of meiosis II, in which cyclin 
s stable and MPF activity is constituitively high. The agent 
~esponsible for this metaphase arrest is termed cytostatic factor 
~CSF) and accordingly this physiologic state is referred to as 
,2SF arrest. Fertilization results in cytosolic Ca 2÷ fluxes that 
werride the CSF arrest and initiate a host of events related to 
:he resumption of cell-cycle progression: MPF activity drops, 
maphase commences, and mitotic cyclins are degraded [4]. 
Extract prepared from unactivated eggs exhibits the CSF arrest 
md can be experimentally manipulated by Ca 2+ addition to 
~nimic all of the events associated with release from CSF arrest 
3]. 
The ubiquitin (Ub) dependent proteolytic system is involved 
a degrading several cytoplasmic proteins [5]. Ub can be co- 
• alently coupled via its carboxy terminus to the epsilon amino 
~:roups of lysine residues in cellular proteins, thereby targeting 
them for destruction. The Ub system consists of an elaborate 
;~rray of enzymes: a series of Ub conjugating enzymes (E 1, E2s 
,nd E3s); a family of isopeptidases that can remove Ub from 
onjugated proteins; and a 26S protease that degrades ubiquiti- 
J Eated proteins [5,6]. An important property of Ub is its ability 
1.5 conjugate to itself thereby forming extended chains on the 
larget protein; substrates conjugated to long Ub chains are 
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more efficiently degraded [7]. This selection is due to the Ub- 
conjugate binding properties of a 26S protease subunit that 
exhibits a higher affinity for polymers containing four or more 
Ub molecules [8]. 
The need for Ub polymers to induce substrate proteolysis has 
been exploited by Hershko and Heller to inhibit Ub dependent 
degradation [9]. They reductively methylated Ub to block all 
lysine epsilon amino groups. The resulting methylated Ub 
(MeUb) can be conjugated to target proteins, but cannot sup- 
port chain elongation. For some substrates, proteolysis i se- 
verely inhibited. 
Several ines of evidence implicate the Ub system in cyclin 
proteolysis. Glotzer et al. working with Xenopus egg extract, 
demonstrated that a cyclin-protein A fusion protein is ubiquiti- 
nated more in mitotic extract than during interphase [10]. 
Hershko et al. showed that MeUb inhibited cyclin proteolysis 
in clam extract; however, they did not detect cyclin-MeUb 
conjugates [11]. More recently Sudakin et al. have fractionated 
the clam extract and identified the cyclosome: a 1500 kDa 
complex that is cell-cycle regulated and was partially purified 
based on its ability to ubiquitinate cyclin fragments [12]. They 
also demonstrated that the cyclosome could ubiquitinate 
bacterially expressed full-length cyclin A purified from inclu- 
sion bodies. Using Xenopus extracts, King et al. [13] confirm the 
existence of a 20S complex that, like the clam cyclosome, is 
activated at mitosis and required for cyclin ubiquitination. 
In these studies, we have detected Ub conjugates of full- 
length Xenopus cyclin B2, thus indicating that prior proteolytic 
cleavage of cyclin is not necessary for its ubiquitination. The 
concentration of Ub-cyclin adducts is highest during the phase 
of rapid cyclin degradation, but Ub-cyclin conjugates can also 
be detected uring CSF arrest and interphase. 
2. Materials and Methods 
Creatine phosphokinase, ATE phosphocreatine, CaCI> calf liver 
tRNA, EGTA, cycloheximide and cytochalasin B were purchased from 
Sigma. Versilube oil was from Andpak-EMA. Amino acid mix minus 
methionine, T7 RNA polymerase, DTT, rNTPs and RNasin were from 
Promega. RNase A, RNase inhibitor, 10 × transcription buffer and 
SphI were from Boehringer Mannheim. mTG(5 ') ppp(5')G was from 
New England Biolabs. [35S]Methionine was from DuPont-New Eng- 
land Nuclear. Rainbow markers were from Amersham. 
2.1. Preparing CSF arrested extract 
Xenopus laev& frogs were induced to ovulate as described previously 
[14]. CSF arrested extract was prepared as described previously [3]. 
Briefly, dejellied eggs were washed 4 times with 100 mM KCI, 0.1 mM 
CaClz, 1.0 mM MgCI> 50 mM sucrose, 10 mM HEPES pH 7.7 and 
twice with the same buffer containing 5 mM EGTA and 0.1 mg/ml 
cytochalasin B. The eggs were spun through versilube oil, for 1 min at 
1000 rpm and 30 s at 2000 rpm, then crushed by centrifugation at10,000 
rpm for 10 rain in a Beckman SW50.1 rotor at 16°C. Extract was 
collected by side puncture, supplemented with cytochalosin B to 10 
/zg/ml and an ATP regenerating system consisting of 10.1 mM ATE 
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288 units/ml creatine phosphokinase, 132 mM phosphocreatine, 200 
mM Tris-HC1, 10mM MgCI2, 20 mM KC1, 1 mM DTT, pH 7.8 was 
added (1/20, v/v). The extract was microfuged for 10 rain at 4°C, then 
held on ice for I 2 h before use. 
2.2. Preparation of cyclin B2 mRNA 
A plasmid containing a full-length Xenopus cyclin B2 clone was 
generously provided by Tim Hunt [15]. The plasmid was linearized with 
SphI. Ten /,tg of plasmid was added to a 100 gl transcription mix 
containing: 10 pl transcription buffer, 0.1 mM rGTP, 1 mM rATP, 
rCTP and rUTP, 5 units mTG(5 ') ppp(5')G, 12.5 mM DTT, 40 units 
RNasin, 40 units T7 polymerase. After 30 min at 37°C rGTP was added 
to a final concentration f 1.1 mM and the reaction was continued for 
another hour. The mRNA was ethanol precipitated, resuspended in
water at 2 10 mg/ml and stored at -80°C. 
2.3. Preparation of FSS]methionine-labeled cyclin B2 
Either interphase xtract from electrically activated eggs (prepared 
as described previously [14]) or CSF arrested extract were used for 
producing in vitro translated cyclin. Both produce cyclin which is de- 
graded in a cell-cycle dependent manner: CSF produced cyclin was used 
in Fig. 1; interphase produced cyclin in Figs. 2 and 3. Extract was 
prepared for in vitro translation by modifications of published proce- 
dures [16,17]. Extract was treated with RNase A at 0.25 pg/ml for 20 
min at 10°C. Then DTT was added to 3 mM and RNasin (Promega) 
and RNase inhibitor (Boehringer Mannheim) were each added to a 
final concentration of 0.5 units/pl. Extract was incubated at 10°C for 
10 min. Then tRNA was added to a final concentration of 0.1 mg/ml 
and an amino acid mixture minus methionine was added to 0.02 mM. 
[35S]Methionine was added to a final concentration of 4.3 ~Ci/pl and 
the reaction was shifted to 23°C. Cyclin mRNA was added (final 
concentrations 0.25-0.6 mg/ml) and the reactions were allowed to pro- 
ceed for either 1 h (CSF extract) or 40 min (interphase extract). Cyclin 
containing extract was stored at -80°C until use. 
2.4. Methylated HisUb preparation 
Six histidine residues were cloned in after the initial methionine of 
the Ub gene and the construct was placed under isopropyl-fl-D-thioga- 
lactopyranoside control using standard recombinant DNA procedures 
[18]. The resulting histidine tagged Ub (HisUb) was expressed in 
Escherichia coli and purified as described [19] except he heat treated 
supernatant was concentrated on a centricon 3 microconcentrator 
(Amicon) and purified on a superdex 75 16/60 sizing column (Pharma- 
cia). Purified HisUb was methylated as described previously [9]. 
2.5. SDS-PAGE 
Samples were dissolved in SDS sample buffer consisting of 0.0625 M 
Tris-HC1, pH 6.8, 2% SDS, 10% glycerol, 5% fl-mercaptoethanol, and 
0.05% Bromophenol blue. Samples were run on 12.5% gels as described [20]. 
3. Results and discussion 
Previous reports have implicated the Ub system in cyclin 
proteolysis [10 13]. Initial evidence, published by Glotzer et al. 
[10], demonstrated Ub conjugates of a cyclin-protein A fusion 
protein. Contemporaneous studies revealed that MeUb inhib- 
ited the degradation of clam cyclin, yet cyclin-Ub conjugates 
were not detected [11]. Additional experiments in which N- 
terminal cyclin fragments were used as proteolytic substrates 
yielded equivocal results with respect o Ub conjugates: Hol- 
loway et al. demonstrated Ub conjugates of the fragments [21], 
while van der Velden and Lohka did not detect them [22]. 
Subsequent reports detailing the fractionation and partial puri- 
fication of the cyclin ubiquitination components have used ei- 
ther cyclin fragments or fusion proteins to assay for these com- 
ponents [12,13,23]. While it is clear that cyclin protein se- 
quences can be ubiquitinated, it is unclear whether ubiquitin 
initiates proteolysis of full-length cyclin or whether a Ub-inde- 
pendent proteolytic leavage destabilizes cyclin allowing the Ub 
system to engage and destroy the resulting fragments. 
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Fig. 1. Degradation of in vitro translated cyclin B2 in Xenopus egg 
extract. CSF arrested extract was prepared as described in section 2, 
cycloheximide was added to a final concentration of 0.1 mg/ml and 
incubated for 5 min at 23°C. Extract containing in vitro translated 
[35S]cyclin was diluted 1:10 into the CSF arrested extract and held for 
I0 min at 23°C. The time course shown (minutes) was initiated by 
adding CaC12 to 0.4 mM, or as a dilution control, H20 was added to 
maintain CSF arrest. At the indicated times 3 pl of extract was re- 
moved, quenched in SDS-sample buffer and analyzed by SDS-PAGE 
followed by autoradiography. The lane labeled 'cyc' shows untreated 
[35S]cyclin. Molecular mass markers are indicated on the left. The 
bracket denotes the position of [35S]cyclin B2. 
To produce a sensitive and physiologically relevant system 
to study cyclin ubiquitination, we synthesized full-length, 
[35S]methionine labeled Xenopus cyclin B2 by in vitro transla- 
tion in nuclease treated Xenopus egg extract. The in vitro trans- 
lated cyclin is an ideal substrate by several criteria: it is the 
physiologic substrate from the same species, thus avoiding 
complications from a heterologous system, it can be metaboli- 
cally labeled with [35S]methionine thereby eliminating potential 
proteolysis artifacts from other labeling procedures [24], and it 
is the only labeled protein in the extract, thereby facilitating 
detection of Ub conjugates. Furthermore, synthesis in Xenopus 
egg extract rather than reticulocyte lysate precludes introduc- 
tion of reticulocyte nzymes in the degradation assay. This 
cyclin is also preferable to cyclin expressed in bacteria where 
the full-length product is insoluble, necessitating denaturing 
conditions during purification that could affect its substrate 
characteristics, Lastly, the in vitro translated cyclin effectively 
mimics the substrate characteristics of endogenous cyclin B2. 
Cyclin is relatively stable in CSF arrested extract, yet is rapidly 
and completely destroyed when Ca 2+ is added to induce cell 
cycle progression. This is evident from the autoradiograms 
presented in Fig. 1. In all experiments, histone H 1 kinase activ- 
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Fig. 2. Effects of Ub or MeHisUb on cyclin stability in 3 cell-cycle phases. CSF extract was prepared and cycloheximide treated as described in 
Fig. 1 legend. The order of manipulations for '+Ca -,+' and 'CSF arrest' lanes was as follows: Extract containing 35S-labeled cyclin was diluted 1:10 
into CSF arrested extract 20 min before CaC12 addition; Ub or MeHisUb was added to a final concentration of 1.6 mg/ml, 10 min before CaCI2 
addition; CaC12 was added to 0.4 mM or  H20 was added as a dilution control in 'CSF arrest' o begin the time course shown (minutes). For 'interphase' 
extract, CaCI2 was added to 0.4 mM; after 30 min a 1/10 volume of 35S-labeled cyclin was added; after 40 min either Ub or MeHisUb were added 
to 1.6 mg/ml. At the indicated times, samples were removed and processed as described in the legend for Fig. 1. Molecular mass markers are shown 
on the left. Untreated cyclin is shown in the lane marked 'cyc'. The bracket denotes the position of [35S]cyclin B2. 
ity was measured as an independent means of monitoring the 
cell-cycle stage of the extract (data not shown). 
In the experiment shown in Fig. 1, we could not visualize any 
higher molecular weight species of cyclin corresponding to Ub 
conjugates. In order to optimize the sensitivity for detecting 
ubiquitinated cyclin species, we added methylated 6-his-tagged 
Ub (MeHisUb) to the extract and monitored its effect on cyclin 
degradation. As a control, an equal concentration of unmodi- 
fied Ub was added. In the experiment shown in Fig. 2, the 
effects of MeHisUb on cyclin degradation were examined in 
three different cell-cycle phases. Cyclin is relatively stable in 
both CSF arrested and interphase xtract (half life ~65 min). 
However, cyclin is rapidly degraded when Ca 2÷ is added to 
release the CSF arrest (half life -8  min). MeHisUb partially 
inhibits cyclin proteolysis and results in a marked accumulation 
of MeHisUb-cyclin conjugates. Unmodified Ub also resulted 
in a modest accumulation of cyclin conjugates, probably due 
to isopeptidase inhibition (see below). 
The levels of cyclin-Ub conjugates are determined by a bal- 
ance between the rates of conjugate formation, disassembly by 
isopeptidases and proteolysis. When the system is unperturbed, 
cyclin-Ub conjugates are not detected (Fig. 1). The equilibrium 
can be shifted to reveal cyclin-Ub conjugates by simply adding 
MeHisUb or unmodified Ub. We believe that both reagents 
exert these effects by partially inhibiting isopeptidases rather 
than stimulating conjugation because addition of C-terminal 
Ub peptide extensions also results in conjugate accumulation 
(unpublished data). The more dramatic effects observed in the 
presence of MeHisUb indicate that it is either a more potent 
isopeptidase inhibitor than Ub or that blocking chain extension 
reactions hifts the equilibrium towards conjugate accumula- 
tion. The His-tag itself has minimal impact on this equilibrium 
shift, as the same effects are seen when MeUb is added to the 
system (data not shown). 
Two lines of evidence indicate that the observed higher mo- 
lecular weight species are Ub conjugates of cyclin. First, cyclin 
is the predominant labeled band so the shifted bands must have 
originated from cyclin. Second, the 6-histidine tag on MeHisUb 
imparts a slight mobility shift to proteins conjugated to it. As 
shown in Fig. 3, cyclin conjugates formed from MeHisUb mi- 
grate slightly slower on SDS PAGE than conjugates formed 
from unmodified Ub. Furthermore, the MeHisUb conjugates 
of cyclin can be purified with a nickel affinity column (data not 
shown). 
The data presented in Fig. 2 show that MeHisUb results in 
an accumulation of cyclin-MeHisUb conjugates. During the 
degradation phase (+Ca2+), conjugates are most prominent and 
cyclin proteolysis partially inhibited. These results are consis- 
tent with the idea that ubiquitination regulates rapid cyclin 
proteolysis. However, because MeHisUb only partially inhibits 
cyclin proteolysis, it is possible that dual pathways exist for 
cyclin degradation. 
An apparent paradox is also evident from the results in Fig. 
2. Ubiquitinated cyclin is observed in CSF arrested and inter- 
phase extract, even though cyclin is not rapidly degraded. Pre- 
sumably, MeHisUb alters the existing equilibrium to result in 
conjugate buildup, indicating that a low, normally undetecta- 
ble, level of cyclin conjugation occurs throughout the cell-cycle. 
This finding is consistent with the results of Glotzer et al. [10] 
who also observed a low level of ubiquitination during inter- 
phase. Interestingly, quantitation of the gels shown in Fig. 2 
show that cyclin's half life during CSF arrest and interphase is
not altered by addition of MeHisUb (data not shown). Al- 
though this might suggest that these conjugates are not prote- 
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Fig. 3. Electrophoretic mobility comparison of cyclin conjugates 
formed with either MeHisUb or unmodified Ub. CSF arrested extract 
was prepared and manipulated xactly as described in Fig. 2 for '+Ca ~+' 
extract. The reactions were quenched 5 minutes after CaC12 addition. 
Extract samples containing either Ub or MeHisUb were loaded in 
alternating lanes and subjected to SDS-PAGE and autoradiography. 
Molecular mass markers are indicated on the left and the bracket on 
the right denotes unconjugated [35S]cyclin B2. 
olytic intermediates, MeHisUb may be a less effective inhibitor 
when the half life of cyclin is 65 min rather than 8 rain. 
Our results indicate that full-length cyclin B2 is a substrate 
for the Ub system and that prior proteolytic processing is not 
a prerequisite for ubiquitination. The observed cyclin-Ub con- 
jugates are approximately the expected molecular weight for 
full-length conjugates. However, drawing firm conclusions 
from the apparent molecular weight of cyclin conjugates is 
difficult; cyclin phosphorylation results in a significant gel mo- 
bility shift [25] and defining absolute molecular weights for Ub 
conjugate ladders has historically been problematical [26]. 
Therefore, the observed conjugates are consistent with ubiquiti- 
nation of the full-length protein, but from this observation 
alone we cannot rule out removal of several amino acids from 
either end of cyclin. To be significant in destabilizing cyclin, the 
putative proteolytic event would be expected to occur only 
during the cyclin degradation phase. Because we observe cyclin 
conjugates during CSF arrest and interphase, the most likely 
explanation is that full-length cyclin is ubiquitinated. 
In summary, Ub conjugates of full length cyclin can be de- 
tected. This finding adds further support for the involvement 
of the Ub pathway in cyclin degradation. However, we also can 
detect cyclin conjugates independent of rapid cyclin proteolysis 
implying that the regulation of cyclin destruction may be more 
complex than simply coupling Ub to cyclin. Lastly, our results 
indicate that full-length cyclin is ubiquitinated, lessening the 
possibility that a prior proteolytic attack targets cyclin frag- 
ments for ubiquitination. 
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